The contract research organisation’s (CRO) chairman Boris Reznik said the East-Asian headquarters - located in Tokyo - were built in response to the increasing complexity of clinical trials.
“While a traditional CRO may have simply used a subcontractor, the challenging nature of modern drug trials requires direct management and optimisation processes to succeed,” he said.
Further, Western pharmaceutical firms are increasingly outsourcing drug development to Japanese firms, said Reznik.
According to the chairman, the Japan office will support “both the Asian domestic market and the American and European markets as they collaborate with Japanese pharmaceutical companies.”
The CRO offers a range of services in clinical, regulatory, pharmacovigilance, and quality assurance, and following acquisitions in Germany and Ukraine, has six regional headquarters in Tokyo, Kiev, Moscow, Dusseldorf, Mumbai and Miami.